Company: ABBV
Filing Date: 2025-02-14
Form Type: S-3ASR
Source: 0001104659-25-014191
Chunk: 15

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: S-3ASR
Chunk 15
---
 |     23.2** | ​ | ​ | Consent of Kirkland & Ellis LLP (included in Exhibit 5.1)                                                                                                                                                                                                              | ​ |
| ​ |     24.1** | ​ | ​ | Power of Attorney (included on the signature page)                                                                                                                                                                                                                     | ​ |
| ​ |     25.1** | ​ | ​ | Form T-1 Statement of Eligibility under the Trust Indenture Act                                                                                                                                                                                                        | ​ |
| ​ |      107** | ​ | ​ | Filing Fee Table                                                                                                                                                                                                                                                       | ​ |

* To be filed by amendment or by a Current Report on Form 8-K. ** Filed herewith. Item 17. Undertakings. (a) The undersigned registrant hereby undertakes: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” table in the effective registration statement; and (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; Provided, however, that: Paragraphs (a)(1)(i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed

II-2

TABLE OF CONTENTS

with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated